Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma.

Area of Science:

• Computational biology
• Oncology
• Genomics

Background:

• Personalized medicine offers tailored treatments based on individual genetic profiles.
• Diffuse large B-cell lymphoma (DLBCL) exhibits significant molecular heterogeneity, complicating treatment strategies.
• Integrating patient-specific data into computational models for DLBCL remains a challenge.

Purpose of the Study:

• To develop a computational model for DLBCL that integrates patient-specific genetic information.
• To simulate signaling pathways and marker gene expression in DLBCL.
• To predict the impact of genetic alterations and targeted therapies on individual DLBCL patients.

Main Methods:

• Developed a computational model of signaling pathways and germinal center marker expression, incorporating over 50 components.
• Integrated clinical and genomic data from 164 DLBCL patients, including mutations, structural variants, and copy number alterations, using the CoLoMoTo notebook.
• Simulated patient-specific genotypes to predict pathway consequences and the efficacy of targeted inhibitors like Ibrutinib.

Main Results:

• The model successfully integrated patient-specific genetic data to simulate signaling pathway alterations in DLBCL.
• Predicted patient-dependent variations in the effectiveness of targeted inhibitors, such as Ibrutinib.
• Demonstrated potential synergies between different therapeutic strategies based on patient-specific modeling.

Conclusions:

• The developed computational model provides a framework for personalized medicine in DLBCL by integrating genomic data.
• Patient-specific simulations can predict treatment responses and identify optimal therapeutic strategies.
• This approach holds promise for improving outcomes and reducing treatment resistance in DLBCL.